{"disease":{"id":"myocardial-perfusion-imaging-adjunct","name":"Myocardial Perfusion Imaging Adjunct","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"adenosine","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adenocard","generic_name":"ADENOSINE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Adenosine receptor A3","drug_class":"Adenosine Receptor Agonist [EPC]","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"regadenoson","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Regadenoson","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"A2A adenosine receptor","drug_class":"Adenosine receptor agonist","quality_score":61,"revenue":null,"mechanism":"Regadenoson is a low affinity A2A adenosine receptor agonist that produces coronary vasodilation and increases coronary blood flow."},{"drug_id":"persantin","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Persantin","company_name":"Boehringer Ingelheim","drug_phase":"phase_1","molecular_target":"Equilibrative nucleoside transporter 4, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ganciclovir","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"dipyridamole","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Persantine","generic_name":"DIPYRIDAMOLE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 1","drug_class":"Platelet Aggregation Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Persantine works by inhibiting platelet activation and aggregation by blocking the equilibrative nucleoside transporter 1."},{"drug_id":"adenosin","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adenosin","company_name":"University of Roma La Sapienza","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4-kinase type 2-alpha, Phosphatidylinositol 4-kinase type 2-beta, Adenosine kinase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lexiscan","indication_name":"Myocardial Perfusion Imaging Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lexiscan","company_name":"Medical University of South Carolina","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Adenosine receptor A1, Adenosine receptor A2a","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"regadenoson","guideline_body":"FDA label","recommendation":"Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.","line_of_therapy":"adj","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}